Annual FCF
-$604.32 M
-$273.69 M-82.78%
September 30, 2024
Summary
- As of February 7, 2025, ARWR annual free cash flow is -$604.32 million, with the most recent change of -$273.69 million (-82.78%) on September 30, 2024.
- During the last 3 years, ARWR annual FCF has fallen by -$752.07 million (-509.03%).
- ARWR annual FCF is now -475.27% below its all-time high of $161.03 million, reached on September 30, 2019.
Performance
ARWR Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$161.50 M
-$31.64 M-24.36%
September 30, 2024
Summary
- As of February 7, 2025, ARWR quarterly free cash flow is -$161.50 million, with the most recent change of -$31.64 million (-24.36%) on September 30, 2024.
- Over the past year, ARWR quarterly FCF has dropped by -$35.05 million (-27.72%).
- ARWR quarterly FCF is now -162.91% below its all-time high of $256.71 million, reached on March 31, 2021.
Performance
ARWR Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$604.32 M
-$71.67 M-13.46%
September 30, 2024
Summary
- As of February 7, 2025, ARWR TTM free cash flow is -$604.32 million, with the most recent change of -$71.67 million (-13.46%) on September 30, 2024.
- Over the past year, ARWR TTM FCF has dropped by -$134.16 million (-28.53%).
- ARWR TTM FCF is now -462.24% below its all-time high of $166.83 million, reached on June 30, 2021.
Performance
ARWR TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ARWR Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -82.8% | -27.7% | -28.5% |
| 3 y3 years | -509.0% | -401.1% | -509.0% |
| 5 y5 years | -475.3% | -401.1% | -509.0% |
ARWR Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -509.0% | at low | -378.6% | +13.4% | -587.9% | at low |
| 5 y | 5-year | -475.3% | at low | -162.9% | +13.4% | -462.2% | at low |
| alltime | all time | -475.3% | at low | -162.9% | +13.4% | -462.2% | at low |
Arrowhead Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$604.32 M(+82.8%) | -$161.50 M(+24.4%) | -$604.32 M(+13.5%) |
| Jun 2024 | - | -$129.87 M(+2.7%) | -$532.65 M(+13.3%) |
| Mar 2024 | - | -$126.45 M(-32.2%) | -$470.16 M(+16.8%) |
| Dec 2023 | - | -$186.50 M(+107.6%) | -$402.70 M(+21.8%) |
| Sep 2023 | -$330.63 M(+75.0%) | -$89.83 M(+33.3%) | -$330.63 M(-3.4%) |
| Jun 2023 | - | -$67.38 M(+14.2%) | -$342.24 M(-3.1%) |
| Mar 2023 | - | -$58.98 M(-48.5%) | -$353.21 M(+49.5%) |
| Dec 2022 | - | -$114.43 M(+12.8%) | -$236.25 M(+25.1%) |
| Sep 2022 | -$188.91 M(-227.9%) | -$101.45 M(+29.5%) | -$188.91 M(+57.8%) |
| Jun 2022 | - | -$78.35 M(-235.1%) | -$119.69 M(+59.8%) |
| Mar 2022 | - | $57.98 M(-186.4%) | -$74.88 M(-160.5%) |
| Dec 2021 | - | -$67.09 M(+108.2%) | $123.85 M(-16.2%) |
| Sep 2021 | $147.75 M(-237.1%) | -$32.23 M(-3.9%) | $147.75 M(-11.4%) |
| Jun 2021 | - | -$33.54 M(-113.1%) | $166.83 M(+1.2%) |
| Mar 2021 | - | $256.71 M(-694.3%) | $164.81 M(-233.9%) |
| Dec 2020 | - | -$43.19 M(+228.6%) | -$123.10 M(+14.2%) |
| Sep 2020 | -$107.75 M(-166.9%) | -$13.14 M(-63.0%) | -$107.75 M(+21.6%) |
| Jun 2020 | - | -$35.56 M(+14.0%) | -$88.63 M(+93.7%) |
| Mar 2020 | - | -$31.19 M(+12.0%) | -$45.76 M(+33.2%) |
| Dec 2019 | - | -$27.85 M(-565.8%) | -$34.36 M(-121.3%) |
| Sep 2019 | $161.03 M(-431.0%) | $5.98 M(-18.1%) | $161.03 M(+6.2%) |
| Jun 2019 | - | $7.30 M(-136.9%) | $151.66 M(+16.9%) |
| Mar 2019 | - | -$19.80 M(-111.8%) | $129.75 M(-3.0%) |
| Dec 2018 | - | $167.55 M(-5042.7%) | $133.73 M(-374.9%) |
| Sep 2018 | -$48.64 M(+52.7%) | -$3.39 M(-76.8%) | -$48.64 M(-10.9%) |
| Jun 2018 | - | -$14.61 M(-7.7%) | -$54.57 M(+5.9%) |
| Mar 2018 | - | -$15.82 M(+6.7%) | -$51.53 M(+0.3%) |
| Dec 2017 | - | -$14.83 M(+59.2%) | -$51.39 M(+61.3%) |
| Sep 2017 | -$31.86 M(-53.3%) | -$9.31 M(-19.5%) | -$31.86 M(-10.1%) |
| Jun 2017 | - | -$11.57 M(-26.2%) | -$35.44 M(-17.3%) |
| Mar 2017 | - | -$15.68 M(-433.4%) | -$42.87 M(+2.0%) |
| Dec 2016 | - | $4.70 M(-136.5%) | -$42.03 M(-38.5%) |
| Sep 2016 | -$68.29 M(+0.9%) | -$12.89 M(-32.1%) | -$68.29 M(+0.1%) |
| Jun 2016 | - | -$19.00 M(+28.0%) | -$68.25 M(+8.9%) |
| Mar 2016 | - | -$14.84 M(-31.1%) | -$62.65 M(-2.8%) |
| Dec 2015 | - | -$21.55 M(+67.7%) | -$64.48 M(-4.7%) |
| Sep 2015 | -$67.68 M(+82.3%) | -$12.86 M(-4.1%) | -$67.68 M(+2.2%) |
| Jun 2015 | - | -$13.40 M(-19.6%) | -$66.21 M(+4.7%) |
| Mar 2015 | - | -$16.67 M(-32.7%) | -$63.23 M(+15.5%) |
| Dec 2014 | - | -$24.75 M(+117.4%) | -$54.75 M(+47.4%) |
| Sep 2014 | -$37.13 M(+92.1%) | -$11.39 M(+9.3%) | -$37.13 M(+18.8%) |
| Jun 2014 | - | -$10.42 M(+27.2%) | -$31.25 M(+18.7%) |
| Mar 2014 | - | -$8.19 M(+14.7%) | -$26.32 M(+16.4%) |
| Dec 2013 | - | -$7.14 M(+29.8%) | -$22.62 M(+17.0%) |
| Sep 2013 | -$19.33 M(+22.2%) | -$5.50 M(+0.1%) | -$19.33 M(+4.5%) |
| Jun 2013 | - | -$5.50 M(+22.4%) | -$18.51 M(+8.8%) |
| Mar 2013 | - | -$4.49 M(+16.7%) | -$17.02 M(+0.7%) |
| Dec 2012 | - | -$3.85 M(-17.7%) | -$16.89 M(+6.8%) |
| Sep 2012 | -$15.82 M | -$4.67 M(+16.7%) | -$15.82 M(+23.5%) |
| Jun 2012 | - | -$4.00 M(-8.3%) | -$12.81 M(+30.3%) |
| Mar 2012 | - | -$4.37 M(+57.3%) | -$9.83 M(+45.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | -$2.78 M(+66.8%) | -$6.75 M(+25.0%) |
| Sep 2011 | -$5.40 M(-29.9%) | -$1.66 M(+61.8%) | -$5.40 M(-13.6%) |
| Jun 2011 | - | -$1.03 M(-20.1%) | -$6.25 M(-10.7%) |
| Mar 2011 | - | -$1.29 M(-9.7%) | -$7.00 M(-6.5%) |
| Dec 2010 | - | -$1.42 M(-43.3%) | -$7.49 M(-2.7%) |
| Sep 2010 | -$7.70 M(-49.7%) | -$2.51 M(+41.3%) | -$7.70 M(+1.3%) |
| Jun 2010 | - | -$1.78 M(+0.2%) | -$7.60 M(+3.9%) |
| Mar 2010 | - | -$1.77 M(+8.6%) | -$7.32 M(-28.4%) |
| Dec 2009 | - | -$1.63 M(-32.4%) | -$10.22 M(-33.2%) |
| Sep 2009 | -$15.32 M(-45.8%) | -$2.42 M(+61.5%) | -$15.32 M(-28.6%) |
| Jun 2009 | - | -$1.50 M(-68.0%) | -$21.46 M(-22.7%) |
| Mar 2009 | - | -$4.68 M(-30.4%) | -$27.77 M(-4.2%) |
| Dec 2008 | - | -$6.73 M(-21.4%) | -$29.00 M(+2.6%) |
| Sep 2008 | -$28.27 M(+14.8%) | -$8.56 M(+9.6%) | -$28.27 M(+7.1%) |
| Jun 2008 | - | -$7.81 M(+32.3%) | -$26.40 M(+7.1%) |
| Mar 2008 | - | -$5.90 M(-1.6%) | -$24.64 M(-3.1%) |
| Dec 2007 | - | -$6.00 M(-10.3%) | -$25.42 M(+3.2%) |
| Sep 2007 | -$24.62 M(+56.6%) | -$6.69 M(+10.6%) | -$24.62 M(+12.4%) |
| Jun 2007 | - | -$6.05 M(-9.5%) | -$21.90 M(+5.9%) |
| Mar 2007 | - | -$6.68 M(+28.3%) | -$20.68 M(+17.2%) |
| Dec 2006 | - | -$5.21 M(+31.1%) | -$17.65 M(+12.2%) |
| Sep 2006 | -$15.73 M(+60.9%) | -$3.97 M(-17.6%) | -$15.73 M(+9.9%) |
| Jun 2006 | - | -$4.82 M(+32.0%) | -$14.30 M(+13.0%) |
| Mar 2006 | - | -$3.65 M(+11.1%) | -$12.66 M(+17.9%) |
| Dec 2005 | - | -$3.29 M(+28.9%) | -$10.73 M(+9.8%) |
| Sep 2005 | -$9.77 M(+227.9%) | -$2.55 M(-19.7%) | -$9.77 M(+16.8%) |
| Jun 2005 | - | -$3.17 M(+83.8%) | -$8.37 M(+34.4%) |
| Mar 2005 | - | -$1.73 M(-25.7%) | -$6.22 M(+24.9%) |
| Dec 2004 | - | -$2.32 M(+103.2%) | -$4.98 M(+67.3%) |
| Sep 2004 | -$2.98 M(+1765.9%) | -$1.14 M(+11.2%) | -$2.98 M(+54.2%) |
| Jun 2004 | - | -$1.03 M(+111.3%) | -$1.93 M(+112.1%) |
| Mar 2004 | - | -$486.90 K(+52.1%) | -$910.90 K(+97.2%) |
| Dec 2003 | - | -$320.20 K(+232.5%) | -$461.90 K(+193.1%) |
| Sep 2003 | -$159.70 K(+48.6%) | -$96.30 K(+1184.0%) | -$157.60 K(+109.0%) |
| Jun 2003 | - | -$7500.00(-80.2%) | -$75.40 K(-35.5%) |
| Mar 2003 | - | -$37.90 K(+138.4%) | -$116.90 K(+21.0%) |
| Dec 2002 | - | -$15.90 K(+12.8%) | -$96.60 K(-10.2%) |
| Sep 2002 | -$107.50 K(+31.4%) | -$14.10 K(-71.2%) | -$107.60 K(-0.6%) |
| Jun 2002 | - | -$49.00 K(+178.4%) | -$108.20 K(+45.0%) |
| Mar 2002 | - | -$17.60 K(-34.6%) | -$74.60 K(-17.0%) |
| Dec 2001 | - | -$26.90 K(+83.0%) | -$89.90 K(+9.8%) |
| Sep 2001 | -$81.80 K(+1.2%) | -$14.70 K(-4.5%) | -$81.90 K(-7.2%) |
| Jun 2001 | - | -$15.40 K(-53.2%) | -$88.30 K(-34.3%) |
| Mar 2001 | - | -$32.90 K(+74.1%) | -$134.30 K(+33.9%) |
| Dec 2000 | - | -$18.90 K(-10.4%) | -$100.30 K(+24.0%) |
| Sep 2000 | -$80.80 K(+129.5%) | -$21.10 K(-65.6%) | -$80.90 K(+35.3%) |
| Jun 2000 | - | -$61.40 K(-5681.8%) | -$59.80 K(-3837.5%) |
| Mar 2000 | - | $1100.00(+120.0%) | $1600.00(+220.0%) |
| Dec 1999 | - | $500.00 | $500.00 |
| Sep 1999 | -$35.20 K(<-9900.0%) | - | - |
| Sep 1998 | $100.00(-97.8%) | - | - |
| Sep 1997 | $4600.00 | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual FCF year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly FCF year-on-year change?
- What is Arrowhead Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM FCF year-on-year change?
What is Arrowhead Pharmaceuticals annual free cash flow?
The current annual FCF of ARWR is -$604.32 M
What is the all time high annual FCF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual free cash flow is $161.03 M
What is Arrowhead Pharmaceuticals annual FCF year-on-year change?
Over the past year, ARWR annual free cash flow has changed by -$273.69 M (-82.78%)
What is Arrowhead Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ARWR is -$161.50 M
What is the all time high quarterly FCF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly free cash flow is $256.71 M
What is Arrowhead Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, ARWR quarterly free cash flow has changed by -$35.05 M (-27.72%)
What is Arrowhead Pharmaceuticals TTM free cash flow?
The current TTM FCF of ARWR is -$604.32 M
What is the all time high TTM FCF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM free cash flow is $166.83 M
What is Arrowhead Pharmaceuticals TTM FCF year-on-year change?
Over the past year, ARWR TTM free cash flow has changed by -$134.16 M (-28.53%)